Table 4.
Efficacy and Safety End Point Event Rates by SSRI Use and Randomized Warfarin vs Rivaroxaban (Matched Cohorts)
| Outcomes | Events/100 Patient‐years (Total Events) | |||
|---|---|---|---|---|
| SSRI Rivaroxaban | No SSRI Rivaroxaban | SSRI Warfarin | No SSRI Warfarin | |
| Safety outcomes | ||||
| Major/NMCR bleeding | 18.47 (72) | 16.87 (124) | 18.66 (87) | 16.81 (118) |
| Major bleeding | 4.62 (18) | 3.94 (29) | 6.43 (30) | 4.27 (30) |
| Efficacy outcomes | ||||
| Stroke/non‐CNS embolism | 1.94 (9) | 1.49 (12) | 3.23 (18) | 3.12 (25) |
| Ischemic stroke | 1.51 (7) | 0.99 (8) | 2.69 (15) | 2.50 (20) |
CNS indicates central nervous system; NMCR, nonmajor clinically relevant; SSRI, selective serotonin reuptake inhibitor.